33.3 C
Vientiane
Monday, April 21, 2025
spot_img

Cision PR Newswire

LoveStudy AI Launches AI-Powered Flashcard, Quiz & Notes Tool to Cut Study Time in Half

SHERIDAN, Wyo., April 22, 2025 /PRNewswire/ -- LoveStudy AI, an innovative online learning platform, officially launches today, empowering students worldwide to study smarter, not harder. Combining cutting-edge AI technology with cognitive science principles, LoveStudy AI transforms traditional study methods into personalized, efficient, and engaging learning experiences that adapt...

Trillium Flow Technologies Successfully Completes Refinancing

STAMFORD, Conn., Jan. 13, 2025 /PRNewswire/ -- Trillium Flow Technologies ("Trillium"), a portfolio company of First Reserve, and a global designer, manufacturer, and aftermarket...

ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow

The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE pro, extending ZEISS' LVC market leadership with treatment for myopia, hyperopia, and mixed...

Neuromodulation Wristband ObeEnd Reduces Heart Rate and Perceived Exercise Exertion

VANCOUVER, BC, Jan. 13, 2025 /PRNewswire/ -- WAT Medical Enterprise collaborated with Concordia University and Mitacs Canada to conduct a study using ObeEnd, the...

Addentax Invests Equity Stake in Fresh Food Marketing Solution Provider, Well Information Technology Corporation

SHENZHEN, China, Jan. 13, 2025 /PRNewswire/ -- Addentax Group Corp. ("Addentax" or the "Company") (Nasdaq: ATXG), an integrated service provider focusing on garment manufacturing,...

LG Innotek Reasserts Its Leadership in the Future Mobility Market at CES 2025

Exhibition booth attracts 65,000 cumulative visitors, showcasing innovative mobility components Innovative technologies presented through a 'User-Centric storytelling' approach elicit strong acclaim, inquiries from...

Dx&Vx Presents a New Paradigm for Next-Generation Infectious Disease Response with the Development of a Universal Vaccine

- Preparing for Phase 2 Global Trials of a Ferritin Platform-Based Virus-Like Particle Universal Coronavirus Vaccine - Based on the Excellent Safety and Immune Response in...